2023 Request for Proposals
Required Online LOI Submission Deadline: 11:59 PM (EST), February 1st, 2023
Invited Full Proposal Submission Deadline: 11:59 PM (EST), April 3rd, 2023
A required Letter of Intent (LOI) and invited full proposals may be submitted in response to this RFP until 11:59 PM (EST) on Feb 1, 2023 and April 3, 2023, respectively.
Applicants will be notified of the invitation to submit full proposals by Feb 22, 2023, and after review, awards will be announced, with a July 1, 2023 start date.
A LOI using the Online Form is required to ensure consistency of the proposed research with the research mission of the Consortium for Medical Marijuana (MMJ) Clinical Outcomes Research as defined by Florida statute, as well as to allow recruitment of external reviewers with subject matter expertise in the proposed area of inquiry.
The Consortium for Medical Marijuana Clinical Outcomes Research is comprised of public and private university member institutions within Florida. The Consortium provides awards to support clinical and translational research related to MMJ to investigators within member institutions.
The Consortium is charged by Florida statute to conduct and support “research that contributes to the body of scientific knowledge on the effects of the medical use of marijuana and informs both policy and medical practice related to the treatment of debilitating medical conditions with marijuana”.
The statute requires “the board to award funds to members of the consortium; requiring the board to collaborate with and authorizing the board to award funds to teaching nursing homes for certain research”.
This award mechanism will consider fully developed research studies that generate novel evidence, as well as studies intended to facilitate the collection and/or analysis of preliminary data that will support future extramural funding applications.
For pilot grants, there needs to be a clearly delineated plan for securing future funding. The Consortium discourages applications that repeat previous research projects with unclear justification for innovation.
|RFP Announcement||October 31st, 2022|
|Online Letter of Intent Deadline||11:59 PM (EST), February 1st, 2023|
|Invited Proposal Submission Deadline||11:59 PM (EST), April 3rd, 2023|
|Notice of Awards||July 1st, 2023|
|Award Funding Period||Level 1: July 1, 2023 through June 30, 2024
Level 2: July 1, 2023 through June 30, 2025*
*dependent on continued state support, and internal board review of progress made towards year 1 goals
All applicant principal investigators (PIs) must be faculty members of Consortium member institutions, which currently include:
There is no restriction on the affiliation of the Co-investigators. All applicants who propose human subject/animal research must comply with their institutional IRB, IACUC, or other regulatory approvals as appropriate.
Applicants may submit only one proposal for this RFP as the PI and there are no restrictions regarding the number of proposals where the investigator is listed as a co-investigator.
An applicant awarded in 3 consecutive cycles must skip one cycle of the grants program.
All proposal submissions will be treated as new submissions regardless of previous participation in the consortium grants program.
The following are Consortium research priorities that were derived in consultation with scientific and subject matter experts, evidence review, input from stakeholder engagement and NIH areas of programmatic interest.
Priority will be given to human subjects research, but preclinical translational research with strong rationale for clinical applicability will also be considered.
Proposals addressing these priorities are highly encouraged: